Approximately 28,000 children and adults are diagnosed with a glioma in the US each year. Treatment outcomes for this disease are poor and there is an urgent need for better drugs. Inspired by successes in other oncology indications, Optyon’s mission is to develop a highly effective antibody-drug conjugate for glioma treatment. We have identified pan-glioma specific antigens and blood-brain barrier transcytosis targets from large patient-derived datasets which we validated in patient samples and model systems. Blavatnik support will be used to partner with a CRO such as Nona Biosciences to generate sets of antibodies an optimal antibody candidates will be selected using an in-house developed high-content screening assay. Milestones include antibody development, final antibody selection and  in vivo validation of ADC efficacy.